SEK142.80
0.14%
Stockholm, Jul 11, 05:29 pm CET
ISIN
SE0000454746
Symbol
BIOT
Sector

Biotage AB Target price 2025 - Analyst rating & recommendation

Biotage AB Classifications & Recommendation:

Hold
40%
Sell
60%

Biotage AB Price Target

Target Price SEK146.88
Price SEK142.80
Potential
Number of Estimates 4
4 Analysts have issued a price target Biotage AB 2026 . The average Biotage AB target price is SEK146.88. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 10 analysts: 0 Analysts recommend Biotage AB to buy, 4 to hold and 6 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Biotage AB stock has an average upside potential 2026 of . Most analysts recommend the Biotage AB stock at Sale.

Sales and Margin forecast 2025, 2026 to 2031

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Billion SEK 2.06 2.11
9.83% 2.58%
EBITDA Margin 26.26% 25.25%
5.06% 3.86%
Net Margin 13.81% 12.56%
5.12% 9.07%

4 Analysts have issued a sales forecast Biotage AB 2025 . The average Biotage AB sales estimate is

SEK2.1b
Unlock
. This is
7.55% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
SEK2.2b 11.22%
Unlock
, the lowest is
SEK2.0b 2.86%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 SEK2.1b 9.83%
2025
SEK2.1b 2.58%
Unlock
2026
SEK2.3b 10.29%
Unlock
2027
SEK2.5b 9.54%
Unlock
2030
SEK4.5b 8.51%
Unlock
2031
SEK4.8b 7.26%
Unlock
2032
SEK5.1b 6.00%
Unlock

4 Analysts have issued an Biotage AB EBITDA forecast 2025. The average Biotage AB EBITDA estimate is

SEK532m
Unlock
. This is
5.02% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
SEK555m 9.56%
Unlock
, the lowest is
SEK505m 0.45%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 SEK540m 15.38%
2025
SEK532m 1.40%
Unlock
2026
SEK669m 25.57%
Unlock
2027
SEK753m 12.66%
Unlock

EBITDA Margin

2024 26.26% 5.06%
2025
25.25% 3.86%
Unlock
2026
28.75% 13.86%
Unlock
2027
29.56% 2.82%
Unlock

4 Biotage AB Analysts have issued a net profit forecast 2025. The average Biotage AB net profit estimate is

SEK265m
Unlock
. This is
3.91% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
SEK279m 9.43%
Unlock
, the lowest is
SEK249m 2.48%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 SEK284m 15.45%
2025
SEK265m 6.70%
Unlock
2026
SEK385m 45.15%
Unlock
2027
SEK460m 19.64%
Unlock

Net Margin

2024 13.81% 5.12%
2025
12.56% 9.07%
Unlock
2026
16.53% 31.61%
Unlock
2027
18.06% 9.26%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2031

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share SEK 3.55 3.31
6.93% 6.76%
P/E 43.14
EV/Sales 5.34

4 Analysts have issued a Biotage AB forecast for earnings per share. The average Biotage AB EPS is

SEK3.31
Unlock
. This is
4.09% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
SEK3.49 9.75%
Unlock
, the lowest is
SEK3.11 2.20%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 SEK3.55 6.93%
2025
SEK3.31 6.76%
Unlock
2026
SEK4.80 45.02%
Unlock
2027
SEK5.75 19.79%
Unlock

P/E ratio

Current 44.91 16.60%
2025
43.14 3.93%
Unlock
2026
29.72 31.11%
Unlock
2027
24.84 16.42%
Unlock

Based on analysts' sales estimates for 2025, the Biotage AB stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 5.74 10.45%
2025
5.34 6.94%
Unlock
2026
4.84 9.33%
Unlock
2027
4.42 8.71%
Unlock
2030
2.53 7.85%
Unlock
2031
2.35 6.77%
Unlock
2032
2.22 5.66%
Unlock

P/S ratio

Current 5.84 9.41%
2025
5.43 7.02%
Unlock
2026
4.92 9.33%
Unlock
2027
4.49 8.71%
Unlock
2030
2.57 7.85%
Unlock
2031
2.39 6.77%
Unlock
2032
2.26 5.66%
Unlock

Current Biotage AB Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HANDELSBANKEN CAPITAL MARKETS
Locked
Locked
Locked Mar 19 2025
BERENBERG
Locked
Locked
Locked Nov 07 2024
HANDELSBANKEN CAPITAL MARKETS
Locked
Locked
Locked Oct 29 2024
Analyst Rating Date
Locked
HANDELSBANKEN CAPITAL MARKETS:
Locked
Locked
Mar 19 2025
Locked
BERENBERG:
Locked
Locked
Nov 07 2024
Locked
HANDELSBANKEN CAPITAL MARKETS:
Locked
Locked
Oct 29 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today